Menu Search
Equities

Accuray Inc

XEJ:STU

Accuray Inc

Actions
  • Price (EUR)1.99
  • Today's Change-0.03 / -1.49%
  • Shares traded0.00
  • 1 Year change-34.11%
  • Beta--
Data delayed at least 15 minutes, as of Apr 30 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells, and supports solutions that are designed to deliver radiation treatments. Its solutions are designed to advance patient care during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, the Company also provides services, which include post-contract customer support (warranty period services and post warranty services), installation services, training, and other professional services.

  • Revenue in USD (TTM)447.48m
  • Net income in USD-14.55m
  • Incorporated2001
  • Employees1.02k
  • Location
    Accuray Inc1240 DEMING WAYMADISON 53717United StatesUSA
  • Phone+1 (608) 824-2800
  • Fax+1 (408) 716-4601
  • Websitehttps://www.accuray.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.